144043-17-4

Basic information

• Product Name: (3R)-(-)-1-BENZYL-3-(METHYLAMINO)PYRROLIDINE
• Synonyms: (3R)-(-)-Benzyl-3-(methylamino)pyrrolidine;(3R)-1-Benzyl-N-methyl-3-pyrrolidinamine;(3R)-(-)-1-BENZYL-3-(METHYLAMINO)PYRROLIDINE
• CAS NO: 144043-17-4
• Molecular Formula: C₁₂H₁₈N₂
• Molecular Weight: 190.28
• Product Categories: Amines and Anilines;Heterocycles;3-Aminopyrrolidines;Amines (Chiral);Chiral 3-Aminopyrrolidines;Chiral Building Blocks;Synthetic Organic Chemistry
• Mol File: 144043-17-4.mol

Chemical Properties

• Boiling Point: 273.066 °C at 760 mmHg
• Flash Point: 105.62 °C
• Appearance: /
• Density: 0,99 g/cm3
• Refractive Index: -3 ° (C=10, EtOH)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.16±0.20(Predicted)
• CAS DataBase Reference: (3R)-(-)-1-BENZYL-3-(METHYLAMINO)PYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: (3R)-(-)-1-BENZYL-3-(METHYLAMINO)PYRROLIDINE(144043-17-4)
• EPA Substance Registry System: (3R)-(-)-1-BENZYL-3-(METHYLAMINO)PYRROLIDINE(144043-17-4)

Safety Data

• Hazard Codes: Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 144043-17-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
(3R)-(-)-1-Benzyl-3-(methylamino)pyrrolidine is used as a key intermediate in pharmaceutical research for the synthesis of biologically active molecules. Its chiral nature and specific stereochemistry allow for the creation of enantiomerically pure compounds, which can have different biological activities and reduce potential side effects.
Used in Organic Synthesis:
In the field of organic synthesis, (3R)-(-)-1-Benzyl-3-(methylamino)pyrrolidine serves as a versatile building block for the development of complex organic molecules. Its structural features enable the formation of various functional groups and the construction of diverse molecular frameworks, facilitating the synthesis of novel compounds with potential applications in various industries.
Used in Drug Development:
(3R)-(-)-1-Benzyl-3-(methylamino)pyrrolidine is utilized in drug development as a precursor for the creation of new pharmaceuticals. Its potential pharmacological properties and the ability to influence biological targets make it an important tool for designing and optimizing drug candidates with improved efficacy and selectivity.
Used in Chemical Research:
In chemical research, (3R)-(-)-1-Benzyl-3-(methylamino)pyrrolidine is employed as a model compound to study the effects of stereochemistry on molecular interactions and reactivity. Its unique structural features provide insights into the relationship between molecular structure and biological activity, contributing to the understanding of molecular recognition and the design of more effective drugs and materials.

Upstream product

• 114715-39-8 (R)-1-benzyl-3-aminopyrrolidine 
• 131878-23-4 (3R)-1-benzyl-3-[(tert-butoxycarbonyl)(methyl)amino]pyrrolidine 
• 131852-54-5 (3R)-(-)-1-benzyl-3-aminopyrrolidine hydrochloride 
• 101385-90-4 (S)-N-benzyl-3-hydroxypyrrolidine 
• 116183-79-0 (3S)-3-<(4-tolylsulfonyl)oxy>-1-(phenylmethyl)pyrrolidine 
• 74-89-5 methylamine 

Downstream Products

• 132920-84-4 (3R)-3-(methylamino)pyrrolidine dihydrochloride 
• 762285-93-8 ((R)-1-benzylpyrrolidin-3-yl)-methyl-carbamic acid 4-nitrophenyl ester 
• 1163123-42-9 ((R)-1-benzyl-pyrrolidin-3-yl)-(6-chloro-benzooxazol-2-yl)-methyl-amine 
• 762285-94-9 [(S)-1-({(R)-1-[3-(4-Chloro-phenyl)-propyl]-pyrrolidin-3-yl}-methyl-carbamoyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester 
• 848464-76-6 [(S)-1-({(R)-1-[2-(4-Chloro-phenoxy)-ethyl]-pyrrolidin-3-yl}-methyl-carbamoyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester 
• 762283-05-6 ((S)-1-{[(R)-1-(4,4-Dimethyl-cyclohexyl)-pyrrolidin-3-yl]-methyl-carbamoyl}-pyrrolidin-3-yl)-methyl-carbamic acid tert-butyl ester 
• 848464-92-6 ((R)-1-{[(R)-1-(4,4-Dimethyl-cyclohexyl)-pyrrolidin-3-yl]-methyl-carbamoyl}-pyrrolidin-3-yl)-methyl-carbamic acid tert-butyl ester 
• 762285-64-3 Methyl-((S)-1-{methyl-[(R)-1-(3-phenyl-propyl)-pyrrolidin-3-yl]-carbamoyl}-pyrrolidin-3-yl)-carbamic acid tert-butyl ester 
• 762285-95-0 (S)-3-Methylamino-pyrrolidine-1-carboxylic acid {(R)-1-[3-(4-chloro-phenyl)-propyl]-pyrrolidin-3-yl}-methyl-amide 
• 848464-75-5 ((S)-1-{[(R)-1-(2-Hydroxy-ethyl)-pyrrolidin-3-yl]-methyl-carbamoyl}-pyrrolidin-3-yl)-methyl-carbamic acid tert-butyl ester 
• 762285-96-1 (S)-3-Methylamino-pyrrolidine-1-carboxylic acid [(R)-1-(4,4-dimethyl-cyclohexyl)-pyrrolidin-3-yl]-methyl-amide 
• 762285-65-4 (S)-3-Methylamino-pyrrolidine-1-carboxylic acid methyl-[(R)-1-(3-phenyl-propyl)-pyrrolidin-3-yl]-amide 
• 762285-62-1 {(S)-1-[((R)-1-Benzyl-pyrrolidin-3-yl)-methyl-carbamoyl]-pyrrolidin-3-yl}-methyl-carbamic acid tert-butyl ester 

Relevant articles and documents

JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF

Janus kinase 1 selective inhibitors and pharmaceutical use thereof are provided.

HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS

Compounds of formula (I) [Formula should be inserted here] and a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, R24, X, L, n and p are as defined in the specification, are useful for treating or preventing Mer tyrosine kinase receptor modulated disease or conditions. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor

A series of 3(R)-aminopyrrolidine derivatives were designed and synthesized for JAK1-selective inhibitors through the modification of tofacitinib's core structure, (3R,4R)-3-amino-4-methylpiperidine. From the new core structures, we selected (R)-N-methyl-N-(pyrrolidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine as a scaffold for further SAR studies. From biochemical enzyme assays and liver microsomal stability tests, (R)-3-(3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile (6) was chosen for further in vivo test through oral administration. Compound 6 showed improved selectivity for JAK1 compared to that of tofacitinib (IC50 11, 2.4 × 102, 2.8 × 103, and 1.1 × 102 nM for JAK1, JAK2, JAK3, and TYK2, respectively). In CIA and AIA model tests, compound 6 exhibited similar efficacy to tofacitinib citrate.

Fluoronaphthyridines and -quinolines as Antibacterial Agents. 5. Synthesis and Antimicrobial Activity of Chiral 1-tert-Butyl-6-fluoro-7-substituted-naphthyridones

A series of novel 7-substituted-1-tert-butyl-6-fluoronaphthyridone-3-carboxylic acids has been prepared.These derivatives are characterized by chiral aminopyrrolidine substituents at the 7 position.In this paper we report the full details of the asymmetric synthesis of this series of compounds.Structure-activity relationship studies indicate that the absolute stereochemistry at the asymmetric centers of the pyrrolidine ring is critical for maintaining good activity.Compounds 60 and 61 (3-amino-4-methylpyrrolidine enantiomers) were selected for preclinical evaluation.